KHK 6188

Drug Profile

KHK 6188

Alternative Names: KHK-6188

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kyowa Hakko Kirin
  • Class Analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 18 Oct 2013 Discontinued - Phase-II for Neuropathic pain in Japan (PO)
  • 11 Jun 2012 Phase-II clinical trials in Neuropathic pain in Japan (PO)
  • 21 Feb 2012 Kyowa Hakko Kirin plans a phase II trial for Postherpetic neuralgia in Japan (NCT01544296)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top